About 412,291 results
Brexanolone injection in post-partum depression: two multicentre, double-blind, randomi... Preview
Lancet (London, England); Meltzer-Brody S, Colquhoun H et. al.

Sep 4th, 2018 - Post-partum depression is associated with substantial morbidity, and improved pharmacological treatment options are urgently needed. We assessed brexanolone injection (formerly SAGE-547 injection), a positive allosteric modulator of γ-aminobutyric-acid type A (GABAA) receptors, for the treatment of moderate to severe post-partum depression. We did two double-blind, randomised, placebo-controlle...

ACOG Committee Opinion No. 742: Postpartum Pain Management. Preview
Obstetrics and Gynecology;

May 21st, 2018 - Pain and fatigue are the most common problems reported by women in the early postpartum period. Pain can interfere with a woman's ability to care for herself and her infant. Untreated pain is associated with a risk of greater opioid use, postpartum depression, and development of persistent pain. Nonpharmacologic and pharmacologic therapies are important components of postpartum pain management....

A Brief Exposure-Based Treatment vs Cognitive Processing Therapy for Posttraumatic Stre... Preview
JAMA Psychiatry; Sloan DM, Marx BP et. al.

Jan 18th, 2018 - Written exposure therapy (WET), a 5-session intervention, has been shown to efficaciously treat posttraumatic stress disorder (PTSD). However, this treatment has not yet been directly compared with a first-line PTSD treatment such as cognitive processing therapy (CPT). To determine if WET is noninferior to CPT in patients with PTSD. In this randomized clinical trial conducted at a Veterans Affa...

Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy ... Preview
JAMA Psychiatry; Daly EJ, Singh JB et. al.

Dec 28th, 2017 - Approximately one-third of patients with major depressive disorder (MDD) do not respond to available antidepressants. To assess the efficacy, safety, and dose-response of intranasal esketamine hydrochloride in patients with treatment-resistant depression (TRD). This phase 2, double-blind, doubly randomized, delayed-start, placebo-controlled study was conducted in multiple outpatient referral ce...

Adjunctive Bright Light Therapy for Bipolar Depression: A Randomized Double-Blind Place... Preview
The American Journal of Psychiatry; Sit DK, McGowan J et. al.

Oct 3rd, 2017 - Patients with bipolar disorder have recurrent major depression, residual mood symptoms, and limited treatment options. Building on promising pilot data, the authors conducted a 6-week randomized double-blind placebo-controlled trial to investigate the efficacy of adjunctive bright light therapy at midday for bipolar depression. The aims were to determine remission rate, depression symptom level...

ATS Conference 2019 - American Thoracic Society

May 14th, 2019 - The American Thoracic Society improves global health by advancing research, patient care, and public health in pulmonary disease, critical illness, and sleep disorders.

Prescription Drug Use in the United States, 2015–2016
Martin. C., et al

May 8th, 2019 - In 2015–2016, 45.8% of the U.S. population used prescription drugs in the past 30 days. Prescription drug use increased with age, from 18.0% of children under age 12 years to 85.0% of adults aged 60 and over. Prescription drug use was highest among non-Hispanic white persons followed by non-Hispanic black persons, and lowest among non-Hispanic Asian and Hispanic persons. The most commonly us...

FDA requires stronger warnings about rare but serious incidents related to certain prescription insomnia medicines

Apr 29th, 2019 - The U.S. Food and Drug Administration today announced the agency is requiring a new boxed warning – the agency’s most prominent warning – on certain prescription insomnia drugs to better ensure patients and their health care professionals have the information they need when considering use of these medicines. The boxed warning follows several reports of rare, but serious injuries and deaths res...

National Institute on Alcohol Abuse and Alcoholism - What Is A Standard Drink?

Apr 28th, 2019 - Many people are surprised to learn what counts as a drink. The amount of liquid in your glass, can, or bottle does not necessarily match up to how much alcohol is actually in your drink. Different types of beer, wine, or malt liquor can have very different amounts of alcohol content. For example, many light beers have almost as much alcohol as regular beer – about 85% as much.

National Institute on Alcohol Abuse and Alcoholism - Brochures and Fact Sheets

Apr 28th, 2019 - This section contains easy-to-read material for the public covering a wide range of alcohol-related topics. Publications listed below are online full text and free of charge unless otherwise noted.

Antioxidant; Camellia sinensis; Free radical; Green tea; Matcha

Apr 18th, 2019 - The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression.

Public Policy Statement on the Ethical Use of Drug Testing in the Practice of Addiction Medicine

Apr 16th, 2019 - Drug testing uses a biological sample to detect the presence of drugs and/or drug metabolites in a patient’s body. Drug tests are ordered by physicians in a range of medical specialties, but drug testing has particular utility in addiction practices. In clinical addiction medicine, drug testing can provide the treating clinician with objective information about a patient’s recent substance u...

Scam Awareness Related to Incident Alzheimer Dementia and Mild Cognitive Impairment: A ... Preview
Annals of Internal Medicine; Boyle PA, Yu L et. al.

Apr 15th, 2019 - Decreased scam awareness may be an early indicator of impending Alzheimer dementia and its precursor, mild cognitive impairment, but prior studies have not systematically examined the associations between scam awareness and adverse cognitive outcomes. To test the hypothesis that low scam awareness is associated with increased risk for incident Alzheimer dementia, mild cognitive impairment, and ...

Effect of Developmentally Adapted Cognitive Processing Therapy for Youth With Symptoms ... Preview
JAMA Psychiatry; Rosner R, Rimane E et. al.

Apr 10th, 2019 - Despite the high prevalence, evidence-based treatments for abuse-related posttraumatic stress disorder (PTSD) in adolescents have rarely been studied. To examine whether developmentally adapted cognitive processing therapy (D-CPT) is more effective than a wait-list condition with treatment advice (WL/TA) among adolescents with PTSD related to childhood abuse. This rater-blinded, multicenter, ra...

Direct-to-consumer genetic testing

Apr 2nd, 2019 - Types of DTC genetic tests A broad range of genetic test types are offered DTC, including: Carrier testing for diseases such as cystic fibrosis and hemochromatosis Pharmacogenomic testing Testing for predisposition to complex diseases such as hereditary cancers, cardiovascular disease and depression Whole exome or genome sequencing Testing to determine ancestry

Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical ... Preview
JAMA Rabinovici GD, Gatsonis C et. al.

Apr 2nd, 2019 - Amyloid positron emission tomography (PET) detects amyloid plaques in the brain, a core neuropathological feature of Alzheimer disease. To determine if amyloid PET is associated with subsequent changes in the management of patients with mild cognitive impairment (MCI) or dementia of uncertain etiology. The Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) study was a single-group, multisit...

ACOG: Sexual Assault

Mar 31st, 2019 - Sexual violence continues to be a major public health problem affecting millions of adults and children in the United States. Medical consequences of sexual assault include sexually transmitted infections; mental health conditions, including posttraumatic stress disorder; and risk of unintended pregnancy in reproductive-aged survivors of sexual assault. Obstetrician–gynecologists and other wom...

World Autism Awareness Day 2 April

Mar 31st, 2019 - On World Autism Awareness Day, we speak out against discrimination, celebrate the diversity of our global community and strengthen our commitment to the full inclusion and participation of people with autism. Supporting them to achieve their full potential is a vital part of our efforts to uphold the core promise of the 2030 Agenda for Sustainable Development: to leave no one behind

Autism Spectrum Disorder (ASD) | Autism | NCBDDD | CDC

Mar 31st, 2019 - Autism Spectrum Disorder (ASD) is a developmental disability that can cause significant social, communication and behavioral challenges. CDC is working to find out how many children have ASD, discover the risk factors, and raise awareness of the signs.

Alcohol Awareness Month – April 2019

Mar 31st, 2019 - Alcohol Awareness Month was established in 1987 to help reduce the stigma so often associated with alcohol addiction by encouraging communities to reach out.